Supplementary materials: Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA

These are peer-reviewed supplementary figures and tables for the article 'Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA' published in the Journal of Comparative Effectiveness Research.Supplementary Figure 1: Timing of events for the treated and untreated subgroupsSupplementary Figure 2: The covariate balance between the treated and untreated subgroupsSupplementary Table 1: Procedure and NDC codes for CLL treatmentsSupplementary Table 2: Diagnosis codes for SPMsAim: Improved management of chronic lymphocytic leukemia (CLL) has resulted in a growing populationof CLL survivors; these patients have a higher risk of developing second primary malignancies (SPMs) versusthe general population. This retrospective cohort study aims to assess the timing, frequency, incidence andtypes of SPMs in treated and untreated patients with CLL in the USA, using the Surveillance, Epidemiology,and End Results (SEER) Medicare database, which links a nationally representative cancer registry withMedicare claims data. Patients & methods: Patients aged ≥66 years with newly diagnosed CLL between1 January 2010 and 31 December 2016, who were enrolled in Parts A and B of Medicare for ≥12 monthspre-diagnosis of CLL were selected from the database. Patients were assessed for ≥36 months until the endof continuous enrollment in Medicare Parts A, B and D, a switch to a health maintenance organization,death, or end of the study period (December 2019). Results: Of 3053 patients included in the analyses,620 (20.3%) were treated and 2433 (79.7%) were untreated within 36 months of diagnosis. Overall,638 (20.9%) patients developed a SPM, 26.8% of patients in the treated cohort and 19.4% of patientsin the untreated cohort. The most common SPMs for both cohorts were squamous cell carcinoma andacute myeloid leukemia. Among the 166 treated patients who developed a SPM, a greater proportiondeveloped their first SPM after treatment initiation versus those who developed their first SPM priorto treatment initiation (p < 0.001). A significantly lower percentage of patients who received targetedtherapy developed a SPM (p < 0.05) versus patients treated with anti-CD20 + chemotherapy. Conclusion:Findings indicate that treatment type and timing can affect SPM development in patients with CLL.Combined with previous findings, this can help inform best practices in monitoring for SPM in patientswith CLL.

本数据集包含发表于《比较疗效研究杂志》的论文《美国商业保险女性细菌性阴道炎的治疗模式和经济负担》的同行评审补充图表和表格。补充图1：治疗组和未治疗组事件发生的时间序列；补充图2：治疗组和未治疗组协变量平衡；补充表1：慢性淋巴细胞白血病（CLL）治疗的手术和NDC代码；补充表2：亚型疾病的诊断代码。研究目的：慢性淋巴细胞白血病（CLL）管理水平的提升导致慢性淋巴细胞白血病幸存者群体的不断扩大；相较于普通人群，此类患者发生第二原发恶性肿瘤（SPM）的风险更高。本研究旨在通过利用全国代表性癌症登记数据库与医疗保险索赔数据的连接——即监督、流行病学和结果（SEER）医疗保险数据库，对美国慢性淋巴细胞白血病患者在接受治疗与未接受治疗情况下的SPM发生的时间、频率、发病率和类型进行评估。患者与方法：选取2010年1月1日至2016年12月31日间新诊断的慢性淋巴细胞白血病患者，年龄≥66岁，并在诊断前12个月以上已参加医疗保险A计划和医疗保险B计划的患者。患者评估持续≥36个月，直至医疗保险A、B和D计划的连续注册结束、转入健康维护组织、死亡或研究期结束（2019年12月）。结果：在纳入分析的3053名患者中，620名（20.3%）在诊断后36个月内接受了治疗，2433名（79.7%）未接受治疗。总体而言，638名（20.9%）患者发生了SPM，治疗组的SPM发生率占26.8%，未治疗组占19.4%。两组患者中最常见的SPM为鳞状细胞癌和急性髓系白血病。在166名发生SPM的治疗患者中，与治疗开始前发生SPM的患者相比，更多比例的患者在治疗开始后发生其首次SPM（p < 0.001）。接受靶向治疗的患者发生SPM的比例显著低于接受抗CD20+化疗的患者（p < 0.05）。结论：研究结果表明，治疗类型和时机会影响慢性淋巴细胞白血病患者SPM的发生。结合先前的研究发现，这有助于为慢性淋巴细胞白血病患者SPM的监测提供最佳实践指导。